Inclisiran Sodium is Used for reducing cholesterol levels in adults with certain genetic disorders or cardiovascular diseases by inhibiting the PCSK9 gene expression in combination with diet and statin therapy. It was first introduced by Novartis Pharmaceuticals Corp in its drug Leqvio on Dec 22, 2021.

Inclisiran Sodium Patents

Given below is the list of patents protecting Inclisiran Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Leqvio	US10125369	PCSK9 iRNA compositions and methods of use thereof	Aug 18, 2034	Novartis
Leqvio	US10131907	Glycoconjugates of RNA interference agents	Aug 24, 2028	Novartis
Leqvio	US10266825	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Nov 04, 2023 (Expired)	Novartis
Leqvio	US10273477	Therapeutic compositions	Mar 08, 2024 (Expired)	Novartis
Leqvio	US10590418	Methods and compositions for RNAi mediated inhibition of gene expression in mammals	Jul 19, 2022 (Expired)	Novartis
Leqvio	US10669544	Therapeutic compositions	Mar 08, 2024 (Expired)	Novartis
Leqvio	US10806791	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec 04, 2028	Novartis
Leqvio	US10851377	Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder	Aug 25, 2036	Novartis
Leqvio	US11078485	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Nov 04, 2023 (Expired)	Novartis
Leqvio	US11530408	Therapeutic compositions	May 18, 2024 (Expired)	Novartis
Leqvio	US8106022	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec 12, 2029	Novartis
Leqvio	US8222222	Compositions and methods for inhibiting expression of the PCSK9 gene	Dec 29, 2027	Novartis
Leqvio	US8232383	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)	Feb 20, 2023 (Expired)	Novartis
Leqvio	US8546143	Compositions and methods for inhibiting expression of a target gene	Apr 23, 2022 (Expired)	Novartis
Leqvio	US8809292	Compositions and methods for inhibiting expression of the PCSK9 gene	May 10, 2027	Novartis
Leqvio	US8828956	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec 04, 2028	Novartis
Leqvio	US9074213	Compositions and methods for inhibiting expression of a target gene	Mar 09, 2022 (Expired)	Novartis
Leqvio	US9370582	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec 04, 2028	Novartis
Leqvio	US9708610	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Jan 01, 2024 (Expired)	Novartis
Leqvio	US9708615	Therapeutic compositions	Mar 08, 2024 (Expired)	Novartis

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳